Combined Treatment of Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) with Clinical Efficacy

Bando, Hiroshi, Yamashita, Hisako, Kato, Yoshinobu, Ogura, Katsunori, Kato, Yoshikane

Abstract

Background: Vildagliptin/Metformin (EquMet) and imeglimin (Twymeeg) are effective oral hypoglycemic agents (OHAs) for patients with type 2 diabetes (T2D). Case Presentation: The patient was a 68-year-old male with T2D and fatty liver for several years. In November 2022, his HbA1c had increased to 8.2%, and he was started on Twymeeg, followed by EquMet. Results: Over the course of four months, the patient’s HbA1c value successfully decreased from 8.2% to 6.7%, and he did not experience any gastrointestinal adverse effects (GIAEs). Discussion and Conclusion: The combined treatment of EquMet and Twymeeg demonstrated clinical efficacy without any adverse effects. The Trials of IMeglimin for Efficacy and Safety (TIMES) provided various evidence of imeglimin’s effectiveness.

Journal

Asploro Journal of Biomedical and Clinical Case Reports

Asploro Journal of Biomedical and Clinical Case Reports 6 (2), 69-75, 2023-04-14

Asploro

Keywords

Details 詳細情報について

CRID: 1050018351908024576

ISSN: 25820370

Web Site: http://repo.lib.tokushima-u.ac.jp/119178

Text Lang: en

Article Type: journal article

Data Source

IRDB

Export